Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsMEX:MEDP 93 EV-to-FCF is 22.57 as of Jul. 25, 2026, which is 13% above its 10-year median of 19.99. GuruFocus rates MEX:MEDP with a GF Score™ of 93/100 and a GF Value™ of MXN6,131.53. The stock has 2 warning signs investors should review. Among 100 Medical Diagnostics & Research companies, Medpace Holdings ranks better than 53% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medpace Holdings's Enterprise Value is MXN287,352 Mil.
Medpace Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was MXN12,731 Mil. Therefore, Medpace Holdings's EV-to-FCF for today is 22.57.
The historical rank and industry rank for Medpace Holdings's EV-to-FCF or its related term are showing as below:
MEX:MEDP'
s EV-to-FCF Range Over the Past 10 Years
Min: 12.78 Med: 19.99 Max: 43.5
Current: 23.21
During the past 13 years, the highest EV-to-FCF of Medpace Holdings was 43.50. The lowest was 12.78. And the median was 19.99.
MEX:MEDP's EV-to-FCF is ranked better than 53% of 100
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.57
vs MEX:MEDP: 23.21
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medpace Holdings's PE Ratio (TTM) for today is calculated as:
Medpace Holdings's share price for today is MXN7022.03.
Medpace Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN305.638.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medpace Holdings EV-to-FCF Related Terms
Medpace Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Medpace Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's EV-to-FCF falls into.
Medpace Holdings's current Enterprise Value is MXN287,352 Mil.
Medpace Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN12,731 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEX:MEDP) has a EV-to-FCF of 22.57 as of Jul. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medpace Holdings and its competitors. This is 13% above median its historical median of 19.99. Over the past decade, Medpace Holdings' EV-to-FCF has ranged from 12.78 to 43.50. According to the industry distribution chart, Medpace Holdings ranks #47 out of 100 companies in the Medical Diagnostics & Research industry, placing it in the top 47%.
Is Medpace Holdings' EV-to-FCF too high?
Medpace Holdings' current EV-to-FCF of 22.57 is 13% above median its 10-year median of 19.99. Over the past 10 years, this metric has ranged from a low of 12.78 to a high of 43.50. The Medical Diagnostics & Research industry median EV-to-FCF is 26.57. Medpace Holdings' value of 22.57 is 15.1% below this industry median. Based on the distribution chart, Medpace Holdings ranks #47 out of 100 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Medpace Holdings has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' EV-to-FCF compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #47 out of 100 companies for EV-to-FCF. This puts Medpace Holdings in the upper half of its industry. The industry median EV-to-FCF is 26.57. Medpace Holdings' value of 22.57 is 15.1% below this benchmark. Historically, Medpace Holdings' own EV-to-FCF has ranged from 12.78 to 43.50 over the past decade. While the company's 10-year median is 19.99 vs. the industry median of 26.57, Medpace Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.57, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current EV-to-FCF of 22.57 is 15.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current EV-to-FCF is 22.57, which is 13% above median its own 10-year median of 19.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current EV-to-FCF of 22.57. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current EV-to-FCF is 22.57, which is 13% above median its 10-year median of 19.99 and 15.1% below the Medical Diagnostics & Research industry median of 26.57. Medpace Holdings' overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current EV-to-FCF is 22.57 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.
Key valuation signals for MEX:MEDP:
EV-to-FCF: 22.57 (13% above median its 10-year median of 19.99)
GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
Industry Position: 15.1% below the Medical Diagnostics & Research median (#47 of 100)
No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
93GF Score
Get the complete analysis for MEX:MEDP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MEDP has been successfully added to your 
